Exhibit 99.1

February 10, 2022

Encision Reports Third Quarter Fiscal Year 2022 Results

Boulder, Colorado, February 10, 2022 -- Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 third quarter that ended December 31, 2021.

The Company posted quarterly net revenue of $1.94 million for a quarterly net loss of $16 thousand, or $0.00 per diluted share. These results compare to net revenue of $2.16 million for a quarterly net income of $599 thousand, or $0.05 per diluted share, in the year-ago quarter. Net income in last year’s quarter included $599 thousand of extinguishment of debt income. Gross margin on net revenue was 52% in the fiscal 2022 third quarter and 51% in the fiscal 2021 third quarter.

The Company posted nine months net revenue of $6.07 million for a nine months net income of $337 thousand, or $0.03 per diluted share. Net income included extinguishment of debt income. These results compare to nine months net revenue of $5.39 million for a nine months net income of $469 thousand, or $0.04 per diluted share, in the year-ago nine months. Net income included extinguishment of debt income. Gross margin on net revenue was 49% in the fiscal 2022 nine months and 51% in the fiscal 2021 nine months. Gross margin in the fiscal 2022 nine months was lower due to higher material costs.

“Total revenue, which included service revenue, decreased 10% from our third quarter revenue of last year,” said Gregory Trudel, President and CEO of Encision Inc. “COVID reduced total surgical procedures and our revenues suffered as a result. We continue to be positive as we assess and navigate the ups and downs of the pandemic market and continuously look for opportunities to serve our customers and to drive adoption. Our sales and marketing efforts are yielding new customers for our EnTouchâ 2X Scissors and we look forward to their contributions as the market bounces back.”

“Service revenue for our third quarter of fiscal 2022 resulted from services performed under a Master Services Agreement with Auris Health, Inc. (“Auris Health”), a part of the Johnson & Johnson family of companies. Under the agreement, we are collaborating on the integration of AEM Technology into monopolar instrumentation produced by Auris Health for advanced surgical applications. This work is ongoing and is reported separately, as service revenue, in our Statement of Operations.”

“In August 2021, we signed a Supply Agreement with Auris Health. During the term of the agreement, Auris has agreed to buy certain AEM® Technology enabled products exclusively from us. We are proud of being awarded this agreement and look forward to our continued relationship with Auris.”

Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company’s actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company’s distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company’s filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.

Unaudited Condensed Statements of Operations

(in thousands, except per share information)

	Three Months Ended					Nine Months Ended
	December 31, 2021			December 31, 2020		December 31, 2021			December 31, 2020
Product revenue	$	1,734		$	1,999	$	5,348		$	5,093
Service revenue		210			164		718			298
Total revenue		1,944			2,163		6,066			5,391
Product cost of revenue		828			976		2,729			2,501
Service cost of revenue		106			81		356			150
Total cost of revenue		934			1,057		3,085			2,651
Gross profit		1,010			1,106		2,981			2,740
Operating expenses:
Sales and marketing		505			581		1,595			1,513
General and administrative		327			373		994			999
Research and development		194			139		584			443
Total operating expenses		1,026			1,093		3,173			2,955
Operating (loss) income		(16	)		13		(192	)		(215	)
Interest expense, extinguishment of debt     income and other income, net		—			586		529			684
(Loss) income before provision for income taxes		(16	)		599		337			469
Provision for income taxes		—			—		—			—
Net (loss) income	$	(16	)	$	599	$	337		$	469
Net (loss) income per share—basic and diluted	$	0.00		$	0.05	$	0.03		$	0.04
Weighted average number of basic shares		11,678			11,583		11,599			11,583
Weighted average number of diluted shares		11,678			11,709		12,045			11,750

Encision Inc.

Unaudited Condensed Balance Sheets

(in thousands)

	December 31, 2021			March 31, 2021
ASSETS
Cash	$	1,424		$	1,474
Accounts receivable, net		1,029			1,024
Inventories, net		1,406			1,446
Prepaid expenses and other assets		149			154
Total current assets		4,008			4,098
Equipment, net		235			266
Right of use asset		856			1,061
Patents, net		189			213
Other assets		31			21
Total assets	$	5,319		$	5,659
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable	$	531		$	390
Secured notes		18			20
Accrued compensation		238			182
Other accrued liabilities		138			282
Accrued lease liability		357			303
Total current liabilities		1,282			1,177
Secured notes		212			220
Accrued lease liability		648			927
Unsecured promissory note		—			533
Total liabilities		2,142			2,857
Common stock and additional paid-in capital		24,304			24,265
Accumulated (deficit)		(21,127	)		(21,463	)
Total shareholders’ equity		3,177			2,802
Total liabilities and shareholders’ equity	$	5,319		$	5,659

Encision Inc.

Unaudited Condensed Statements of Cash Flows

(in thousands)

	Nine Months Ended
	December 31, 2021			December 31, 2020
Operating activities:
Net income	$	337		$	469
Adjustments to reconcile net income to cash (used in) provided by operating activities:
Extinguishment of debt income		(533	)		(599	)
Depreciation and amortization		86			68
Share-based compensation expense		30			25
Other income from release of accounts payable		—			(56	)
(Recovery from) doubtful accounts, net		(35	)		(31	)
(Recovery from) provision for inventory obsolescence, net		(28	)		24
Changes in operating assets and liabilities:
Right of use asset, net		(20	)		68
Accounts receivable		30			(130	)
Inventories		67			80
Prepaid expenses and other assets		(5	)		(108	)
Accounts payable		142			87
Accrued compensation and other accrued liabilities		(88	)		212
Net cash (used in) provided by operating activities		(17	)		109
Investing activities:
Acquisition of property and equipment		(18	)		(4	)
Patent costs		(13	)		(16	)
Net cash (used in) investing activities		(31	)		(20	)
Financing activities:
Net proceeds from options exercised		8			—
(Paydown of) credit facility, net change		—			(371	)
(Paydown of) secured  notes		(10	)		—
EIDL loan		—			152
Unsecured promissory note		—			599
Net cash (used in) generated by financing activities		(2	)		380
Net (decrease) increase in cash		(50	)		469
Cash, beginning of period		1,474			385
Cash, end of period	$	1,424		$	854